Key Points
- CEO Joshua Cohen sold 1,974 shares on Jan. 16 at an average price of $13.83 for about $27,300, trimming his stake by 0.06% to 3,379,465 shares (SEC filing) valued at roughly $46.74 million.
- AMLX recently traded around $16.55 with a 50‑day SMA of $13.17 and 200‑day SMA of $11.75, a one‑year range of $2.60–$16.96, market cap of about $1.82 billion, and a negative P/E of -9.19.
- Analysts are mixed but the consensus is a Moderate Buy with a $17.25 average price target; the coverage includes 2 Strong Buy, 9 Buy, 2 Hold and 1 Sell ratings, and some firms have raised targets to ~$20.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CEO Joshua Cohen sold 1,974 shares of the business's stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $13.83, for a total value of $27,300.42. Following the transaction, the chief executive officer directly owned 3,379,465 shares in the company, valued at $46,738,000.95. The trade was a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Amylyx Pharmaceuticals Price Performance
Shares of Amylyx Pharmaceuticals stock opened at $16.55 on Wednesday. The business has a fifty day simple moving average of $13.17 and a two-hundred day simple moving average of $11.75. Amylyx Pharmaceuticals, Inc. has a 1 year low of $2.60 and a 1 year high of $16.96. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.19 and a beta of -0.31.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. As a group, equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.
Analysts Set New Price Targets
AMLX has been the subject of several research reports. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, December 20th. Citigroup increased their target price on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a "buy" rating in a research note on Friday, October 17th. HC Wainwright lifted their price target on Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the stock a "buy" rating in a report on Friday, November 7th. Lifesci Capital upgraded Amylyx Pharmaceuticals to a "strong-buy" rating in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $17.25.
Get Our Latest Stock Analysis on AMLX
Institutional Investors Weigh In On Amylyx Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals during the second quarter worth approximately $28,000. Ameritas Investment Partners Inc. acquired a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at $45,000. BNP Paribas Financial Markets lifted its position in shares of Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock valued at $47,000 after acquiring an additional 5,904 shares during the period. Legal & General Group Plc acquired a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $47,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Amylyx Pharmaceuticals in the third quarter worth $48,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.
Amylyx Pharmaceuticals Company Profile
(
Get Free Report)
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
